Titanovo Logo
Back to Cell Types

PeerHomo sapiens (Human)Cancer cell line

Also known as: PEER

🤖 AI SummaryBased on 14 publications

Quick Overview

T-cell acute lymphoblastic leukemia cell line with unique immunophenotype

Detailed Summary

The Peer cell line is a T-cell acute lymphoblastic leukemia (T-ALL) cell line established from a 4-year-old female patient. It exhibits an atypical immunophenotype, lacking typical T-cell markers such as sheep erythrocyte rosette formation and certain anti-T-cell sera, but expressing other T-cell antigens. The cell line shows focal acid phosphatase activity and has been characterized for its unique surface markers and enzyme profiles. Peer is used in research related to T-cell leukemia, particularly in studying T-cell differentiation and leukemic transformation. It has been analyzed for its HLA type, gene expression, and potential neo-epitopes, contributing to cancer immunotherapy research.

Research Applications

T-cell leukemia researchImmunophenotyping studiesLeukemic transformation studiesCancer immunotherapy research

Key Characteristics

Atypical T-cell immunophenotypeFocal acid phosphatase activityUnique surface marker profileHLA typing and neo-epitope analysis
Generated on 6/17/2025

Basic Information

Database IDCVCL_1913
SpeciesHomo sapiens (Human)
Tissue SourcePeripheral blood[UBERON:UBERON_0000178]

Donor Information

Age4
Age CategoryPediatric
SexFemale
Subtype FeaturesNKX2-5

Disease Information

DiseasePrecursor T-cell acute lymphoblastic leukemia
LineageLymphoid
SubtypeT-Lymphoblastic Leukemia/Lymphoma
OncoTree CodeTLL

DepMap Information

Source TypeHSRRB
Source IDACH-000519_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Tyr163Cys (c.488A>G)Unspecified-PubMed=12884349
MutationSimpleNOTCH1p.Leu1600Pro (c.4799T>C)Unspecified-PubMed=22675565
Gene fusionABL1NUP214-ABL1-NUP214 exon 32 fused to ABL1 exon 2PubMed=35354797, PubMed=15361874

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
11,14
D16S539
8,13
D18S51
11,15
D19S433
13
D21S11
28,33.2
D2S1338
20
D3S1358
15
D5S818
12
D7S820
10,12
D8S1179
15
FGA
24
Penta D
11,13
Penta E
13,15
TH01
7,8
TPOX
11
vWA
17,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.

Lehtio J., Vesterlund M., Jafari R.

Nat. Commun. 13:1691.1-1691.19(2022).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

High accuracy mutation detection in leukemia on a selected panel of cancer genes.

Cools J., Aerts S.

PLoS ONE 7:E38463-E38463(2012).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Activation of TLX3 and NKX2-5 in t(5;14)(q35;q32) T-cell acute lymphoblastic leukemia by remote 3'-BCL11B enhancers and coregulation by PU.1 and HMGA1.

Kaufmann M., Meyer C., Drexler H.G., MacLeod R.A.F.

Cancer Res. 67:1461-1471(2007).

DOIPubMed

Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.

Langerak A.W.

Leukemia 21:230-237(2007).

DOIPubMed

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.

Science 306:269-271(2004).

DOIPubMed

Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.

Marynen P., Hagemeijer A.

Nat. Genet. 36:1084-1089(2004).

DOIPubMed

Establishment and characterization of a new leukaemic T-cell line (Peer) with an unusual phenotype.

Minowada J., Verbi W., Greaves M.F.

Int. J. Cancer 25:705-710(1980).

DOIPubMed

Corrigendum to: Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24 (2000), 255-262.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 25:275-278(2001).

DOIPubMed

Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.

Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.

Leuk. Res. 24:255-262(2000).

DOIPubMed

Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.

Sekiya T., Hayashi Y.

Leuk. Res. 23:115-126(1999).

DOIPubMed

Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies.

Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.

Leuk. Res. 23:19-27(1999).

DOIPubMed

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

DOIPubMed

p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.

Einhorn S.

Eur. J. Haematol. 56:313-318(1996).

DOIPubMed

Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.

Uppenkamp M.J., Nowrousian M.R., Seeber S., Opalka B.

Br. J. Haematol. 91:350-354(1995).

DOIPubMed

Interferon system defects in malignant T-cells.";

Xu B., Einhorn S.

Leukemia 8:425-434(1994).

PubMed

Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.

Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.

Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).

DOIPubMedPMC

Antigens specific for human T-lymphocytes detected by xenoantisera to HD-MAR cells: their differential expression on various T-cell lines.

Schlesinger M.

Hum. Immunol. 4:219-228(1982).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:537-548(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:549-559(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:209-229(1985).

DOIPubMed

Introduction of T cell receptor (TCR)-alpha cDNA has differential effects on TCR-gamma delta/CD3 expression by PEER and Lyon-1 cells.

Terhorst C.P., Spits H., de Vries J.E.

J. Immunol. 142:3634-3642(1989).

DOIPubMed

Revision of the chromosome anomalies of the T-cell malignant cell line PEER.

Massaad-Massade L., Venuat A.-M., Remvikos Y., Dutrillaux B.

Ann. Genet. 33:76-78(1990).

PubMed

Characterization of three T-lymphoid cell lines with distinct sensitivities to deoxyadenosine plus deoxycoformycin.

Duan D.-S., Smith W., Sadee W., Cowan M.J.

Thymus 19:1-11(1992).

PubMed

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Web Resources

de.wikipedia.org